Australia & American Society of Clinical Oncology

Australia: Australia participated in the international OPTIMA trial, contributing to the global validation of the Prosigna test's effectiveness in breast cancer treatment.

American Society of Clinical Oncology: The American Society of Clinical Oncology is hosting its annual meeting where the groundbreaking results of the OPTIMA trial are being presented, disseminating the findings to a global audience of cancer specialists.

Australia: Australian researchers and The Australia Institute are involved in the trial.

American Society of Clinical Oncology: ASCO's chief medical officer called the results a 'monumental leap forward,' and the organization hosted the Phase 2 data presentation.

Australia: Australia>>> is one of the countries where patients were enrolled for the KEYNOTE-942 trial, contributing to the global scope of the research. Its involvement highlights its participation in international medical studies.

American Society of Clinical Oncology: The American Society of Clinical Oncology>>> is hosting the presentation of the trial results, solidifying its role as a central platform for disseminating significant cancer research. This event enhances its prestige and influence within the oncology community.